Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept.
Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept.
复制标题
DOI：
10.4110/in.2022.22.e37
复制
发表时间：
2022-10
期刊：
影响因子：
6
通讯作者：
Payne AS
中科院分区：
文献类型：
--
作者：
Oh S;Payne AS
Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with monoclonal Abs targeting B cell lineage markers is standard care therapy for several B cell-mediated autoimmune disorders. In the last 5 years, genetically-engineered cellular immunotherapies targeting B cells have shown superior efficacy and long-term remission of B cell malignancies compared to historical clinical outcomes using B cell depletion with monoclonal Ab therapies. This has raised interest in understanding whether similar durable remission could be achieved with use of genetically-engineered cell therapies for autoimmunity. This review will focus on current human clinical trials using engineered cell therapies for B cell-associated autoimmune diseases.
登录
查看更多内容
影响因子：
64.5
作者：
AMAGAI, M;KLAUSKOVTUN, V;STANLEY, JR
通讯作者：
STANLEY, JR
影响因子：
3.3
作者：
Behin A;Le Panse R
通讯作者：
Le Panse R
影响因子：
39.2
作者：
Devauchelle-Pensec, Valerie;Mariette, Xavier;Saraux, Alain
通讯作者：
Saraux, Alain
DOI：
10.4049/jimmunol.1000466
发表时间：
2011-04-15
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Jacob N;Guo S;Mathian A;Koss MN;Gindea S;Putterman C;Jacob CO;Stohl W
通讯作者：
Stohl W
影响因子：
3.9
作者：
Chowdhury F;Tappuni A;Bombardieri M
通讯作者：
Bombardieri M